Actinium Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.58) Per Share (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) – Analysts at B. Riley issued their Q2 2024 earnings per share estimates for Actinium Pharmaceuticals in a report issued on Wednesday, May 1st. B. Riley analyst Y. Zhi forecasts that the biotechnology company will earn ($0.58) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.48) per share. B. Riley also issued estimates for Actinium Pharmaceuticals’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.49) EPS and FY2025 earnings at ($0.45) EPS.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter.

ATNM has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, April 29th. Maxim Group lifted their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $25.72.

Actinium Pharmaceuticals Trading Down 0.6 %

NYSEAMERICAN:ATNM opened at $8.79 on Monday. The stock has a market capitalization of $261.62 million, a price-to-earnings ratio of -5.14 and a beta of 0.08. Actinium Pharmaceuticals has a 1-year low of $4.00 and a 1-year high of $9.86.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Brandywine Global Investment Management LLC acquired a new position in Actinium Pharmaceuticals during the 3rd quarter worth approximately $1,033,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the last quarter. Finally, Sanders Morris Harris LLC bought a new stake in shares of Actinium Pharmaceuticals in the first quarter worth $78,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.